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1. Introduction
Epithelial tissue constitutes a barrier between organs and the environment. The 
epithelium lines external surfaces of internal organs and inner surfaces of the walls 
of blood vessels. It is also a tissue that exocrine and endocrine glands consist of.
As they separate the organism from the outer environment, the epithelial 
structures form the first line of defense against external factors but, at the same 
time, an entry gate for them influencing the development of the body’s microbiome 
and autoimmune diseases, which are associated with the disorders of microbiome 
composition (dysbiosis) [1, 2]. The epithelium, also as a target for viruses, interacts 
with the invading pathogens and is actively involved in immune response, whose 
course depends on particular genetic and epigenetic conditions.
Epithelial cells are often subject to apoptosis, which makes them an important 
source of autoantigens. Moreover, in many autoimmune diseases, epithelial cells 
are damaged, which leads to further release and exposition of autoantigens, with 
the epithelium being subject to the immune response. For example, thyrocytes 
are responsible for providing the main immunogens (e.g., thyroglobulin, thyroid 
peroxidase, TSH receptor) in autoimmune thyroiditis [3], synoviocytes are a source 
of cyclic citrullinated peptides in rheumatoid arthritis, and oligodendrocytes in 
multiple sclerosis or pancreatic endocrine glandular epithelium (beta-cells) in type 
1 diabetes are a source among others of proinsulin or glutamic acid decarboxylase 
[4]. Hence the suggestion puts forward that autoimmune diseases could be other-
wise classified as the autoimmune inflammation of the epithelium [5]. However, 
there are autoimmune diseases which, due to their effect on the exocrine glands, 
are particularly associated with epithelial damage and an autoimmune process, the 
primary Sjögren’s syndrome (pSS) among them. The primary Sjögren’s syndrome is 
an autoimmune disease in which the exocrine glandular epithelium is a main source 
of autoantigens—such as Ro/SS-A and La/SS-B ribonucleoproteins [6]. Quite often 
pSS may coexist with another autoimmune disorder—a primary biliary cholangitis 
(PBC). In PBC the epithelium (biliary epithelial cells of small bile duct) is the 
starting point of the autoimmune process [7]. The pathogenesis of both diseases 
is similar, with the significant role of epithelial cell apoptosis. Table 1 presents the 
immunological and main clinical features of pSS and PBC.
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The Sjögren’s syndrome is an example of the development of an autoimmune epi-
thelitis and consequences of such a process. The impact of environmental factors on the 
genetically susceptible subject is vital for the development of pSS. There are multiple 
genes (e.g., HLA-B8, HLA-Dw3, HLA-DR3, and DRw52) responsible for the individual’s 
susceptibility to the pSS development. Particular attention has been paid to the genes 
for interferon regulatory factor 5 (IRF5), signal transducer and activator of transcrip-
tion 4 (STAT4) in the type I interferon (IFN) system, and B lymphocyte kinase (BLK) 
involved in B-cell activation, which are considered as risk loci in pSS development [10]. 
Additionally it has been recently revealed that also epigenetic mechanisms, such as 
DNA methylation, histone modifications, and noncoding RNAs, may influence expres-
sion of the involved genes in autoimmune diseases, including pSS [11].
The pSS development is associated with the infection with viruses, which mainly 
target B cells or display tropism to lacrimal and salivary glands. Such a strong 
association has been confirmed in case of the Epstein–Barr virus, as well as other 
viruses: Cytomegalovirus, herpes simplex virus, and hepatitis C virus [12].
Primary Sjögren’s syndrome Primary biliary cholangitis
Exocrine glands Liver
Chronic autoimmune disease Chronic autoimmune disease
Anti–SS-A and anti–SS-B antibodies Anti-mitochondrial antibodies (AMA)
ANA antibodies ANA antibodies may be present
Exocrine glandular epithelium Biliary epithelial cells
Predominance of CD4+ infiltrate around the 
salivary duct
Granuloma and predominance of CD4+ infiltrate around 
the bile duct
Woman > men Woman > men
Fifth decade of life Fifth decade of life
Primary/secondary to other autoimmune 
diseases
Primary/secondary to other autoimmune diseases
Genetic factors—variability in genetic factors Genetic factors—predominant role
Infectious initiating factors: Herpesviridae 
particularly Epstein–Barr virus, CMV, herpes
Infectious initiating factors: Escherichia coli, Helicobacter 
pylori
EBV
Symptoms of eye and mouth dryness
Extraglandular manifestations (organ 
impairment, vasculitis, neuropathy)
Fatigue, pruritus, skin hyperpigmentation, 
hepatosplenomegaly
Liver cirrhosis (late stage with ascites, jaundice, hepatic 
encephalopathy, upper digestive bleeding)
Lymphoma Hepatocellular carcinoma
EULAR/ACR criteria for diagnosis (2016)
1. Labial salivary gland biopsy (focal 
lymphocytic sialadenitis) FS ≥ 1 3 points
2. Anti–SS-A/Ro positivity 3 points
3. OSS ≥5 (or van Bijsterveld score ≥ 4 1 
point
Schirmer’s test ≤5 mm/5 min 1 point
4. Unstimulated salivary flow ≤0.1 mL/min 
1 point
Diagnosis ≥4 point
Exclusions:
Diagnostic criteria for PBC
1. Elevated alkaline level of >2× ULN or elevated 
gamma-glutamyltransferase level of >5× ULN
2. Positivity for AMA antibodies
3. Chronic granulomatous cholangitis at liver biopsy
Diagnosis presence of at least two of the three criteria
ULN, upper limit of normal.
Table 1. 
The immunological and main clinical features of pSS and PBC [8, 9].
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The epithelitis in pSS starts with an influence of certain external factors, such 
as viruses, rare bacteria, or ultraviolet radiation on epithelial cells. This leads to 
cell apoptosis and expression of autoantigens (SS-A and SS-B ribonucleoproteins), 
which are presented to autoreactive T cells. As it is recently highlighted in the lit-
erature, endothelial cells have, therefore, antigen presentation properties, although 
this is not their main feature, as it is the case with antigen-presenting cells (APCs), 
such as dendritic cells, macrophages, and B cells. Also salivary gland epithelial cells 
(SGEC) express MHC class I and MHC class II (HLA-DR) molecules and functional 
co-stimulator B7.1 (CD80) and B7.2 (CD86) molecules and may transmit signals to T 
lymphocytes as nonprofessional APCs [13, 14].
Other processes responsible for the development at this stage include the activa-
tion of the innate immune system, with the activation of Toll-like receptors (espe-
cially TLR3, TLR7, TLR9) and the production of interferon alpha (IFN-α) by plasma 
dendritic cells (pDCs) stimulating epithelial cells, dendritic cells, and neutrophils 
for the production of the B-cell stimulating factor and APRIL [15]. There are 
infiltrates in the exocrine glands initially composed mainly of T cells, whereas the 
activation of B lymphocytes by growth factors, such as BAFF and APRIL, results in 
hypergammaglobulinemia and the production of anti–SS-A and anti–SS-B auto-
antibodies as a secondary immune response. B cells and macrophages also produce 
proinflammatory cytokines, chemokines, and adhesion molecules.
The disease starts with the epithelial inflammation and impaired function of 
the exocrine glands manifesting themselves, for example, in the enlargement of the 
glands and reduction of the secretion of saliva or tears. It evolves then into the phase 
of systemic disease with the organ involvement and general manifestations (fever, 
weight loss, fatigue). Although the Sjögren’s syndrome is most often associated with 
the functional impairment of lacrimal and salivary glands (symptoms included in 
the current criteria of diagnosis [16]), it also affects glands of the digestive system, 
pancreas, liver, gall bladder, respiratory glands, and even sweat glands. Their 
function is impaired through the reduction of secretion of the aqueous phase and 
changes in density of the secretion, leading to the emergence of various clinical 
features: from the feeling of mouth or eye dryness, through recurrent cholelithiasis 
and nephrolithiasis, to stones in the salivary glands.
The consequence of the involvement of epithelia in pSS and its damage is the 
emergence of the way of entry for pathogens in the alimentary tract (from the oral 
cavity to the rectum), as well as in the respiratory tract. In the case of imbalance of 
the microbiome and the occurrence of dysbiosis, also commensals, which become 
potential pathogens in such circumstances, may cross the damaged epithelial bar-
rier. Proteins from the epithelial cells of the mouth, intestines, and skin, as well as 
bacterial (commensal) proteins, may initiate an immune response to Ro60 (theory 
of Ro60-reactive B cells) and activation of T cells, as consequence of molecular 
mimicry [17]. The role of fungal (Candida) infections in pSS development was also 
studied, revealing there was no significant relationship between Candida albicans 
and the rate and amount of salivary secretion, although such relationship was found 
in pathogenic species, such as C. tropicalis, C. glabrata, and C. krusei [18].
In Table 2 the main clinical manifestations of pSS resulting from the epithelial 
damage are presented.
What is particularly important, continuous stimulation of B lymphocytes 
by activating agents, primarily BAFF and APRIL, causes germinal center (GC) 
formation and the formation of secondary lymphoid tissue, which in turn leads 
to the increased risk of lymphoma development. The most common lymphoma 
emerging in the course of pSS is the marginal zone B-cell lymphoma (MZBCL), the 
mucosa-associated lymphoid tissue (MALT) type being predominant. The diffuse 
large B-cell lymphoma (DLBCL), rare T-cell lymphoma, or NK-cell lymphoma are 
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less common. The occurrence of MZBCL has been observed in about 8% of pSS 
patients; it is 40 times higher than in the healthy population [21, 22].
2. Focusing on MALT lymphoma
The most important feature of MALT lymphoma is the presence of neoplastic 
cells (mainly B cells, as well as T cells) within epithelial structures, which may lead 
to destruction of the glandular architecture, also because of the formation of solid 
infiltrations.
Lymphomas in pSS are predominantly localized in salivary glands, which has 
been confirmed in many studies [23], whereas in the general population, MALT 
lymphoma is most often located in the stomach. The occurrence of MALT lymphoma 
in the stomach is proven to be associated with H. pylori infection [24]. The primary 
division of MALT lymphomas depending on the location is shown in Table 3.
Subtypes of lymphoma due to localization
MALT NALT Nasopharynx-
associated lymphoid 
tissue
BALT Bronchus-associated 
lymphoid tissue
LALT Larynx-associated 
lymphoid tissue
GALT Gut-associated 
lymphoid tissue
SALT Skin-associated lymphoid tissue
CALT Conjunctiva-associated lymphoid tissue
SDALT Salivary duct-associated lymphoid tissue
O-MALT Organized mucosa-associated lymphatic tissue-specific type of MALT affecting Waldeyer’s 
tonsillar ring
D-MALT Diffuse mucosa-associated lymphatic tissue-specific type of the disease, cells not organized 
into a separate macroscopically and anatomically identifiable mass, but spread throughout the 
mucosa of different organs
Table 3. 
Division due to the localization of MALT lymphoma [22, 25].
Localization Effect
Nasal and oral 
cavity
Oral candidiasis, dental caries, periodontitis otitis media, dry nose, chronic sinusitis, 
nasal bleeding, weakening of the sense of smell
Bronchi Difficulty in swallowing, dry cough, hoarseness, recurrent bronchitis and less frequent 
bronchioles, bronchial hyperresponsiveness and accompanying dry cough, infections
Lungs Interstitial lung disease
Stomach Chronic gastritis, malabsorption, susceptibility to H. pylori infection
Gut Celiac disease, colitis
Gluten sensitivity [19, 20]
Liver Hepatitis, cholangitis
Pancreas Pancreatitis
Kidneys and 
urine tract
Interstitial nephritis with distal renal tubular acidosis (dRTA). Glomerulonephritis with 
coexisting cryoglobulinemia and urolithiasis
Table 2. 
The main clinical manifestations of pSS due to the epithelial damage.
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3.  Sjögren’s syndrome and primary biliary cholangitis as autoimmune 
epithelitis: general rules for treatment
3.1 The treatment of primary Sjögren’s syndrome involves a dual approach
• A topical treatment, which aims to protect the epithelial barrier of the eye, oral 
cavity, and vagina
• Inhibition of organ changes, as well as the elimination of general symptoms, 
such as fatigue, fever, malaise, or lymphadenopathy [26, 27]
3.1.1 Topical treatment
1. Oral cavity
A.  Saliva substitutes: hydroxymethylcellulose-containing oral spray, proper 
hydration by consuming more liquids, and regularly rinsing the mouth
The stimulation of salivary flow, obtained with the use of pilocarpine or cevime-
line, parasympathomimetics, and muscarinic agonists affecting M1 and M3 recep-
tors, after considering possible contraindications for their use.
Antifungal and antimicrobial treatment with medications such as chlorhexidine; 
the use of nonfluoride remineralizing agents as concomitant therapy.
Diet modification is recommended: eating slightly acidic products such as 
lemon, supplementing diet with unsaturated fatty acids (omega-3), and avoiding 
sweets and sweet effervescent beverages.
Quitting smoking is strongly recommended.
2. Dry eye
A.  The modification of environmental factors, which may increase the dry eye 
symptoms, such as air condition, exposure to dust, and prolonged work at 
computer screen.
When possible, the discontinuation of treatment with medications resulting in 
the reduction of tears or disruption of their composition.
Artificial tears, gels, ointments, special contact lenses, topical autologous serum, 
and special contact lenses.
Punctual plugs (temporary or permanent).
The eyelid therapy: massages and warm compresses.
The eyelid surgery (e.g., blepharoplasty).
Topical immunosuppression: steroids and cyclosporine A.
3. Vaginal dryness
Vaginal dryness treatment is based on the use of intimate moisturizers and 
sexual lubricants and pH balance stabilizers free from hormones and skin irritants. 
In some cases the use of estrogen topical medication may be found useful.
3.1.2 General treatment
Immunosuppressive drugs such as azathioprine, methotrexate, leflunomide, 
mycophenolic acid, cyclosporine A (topical, rare oral), and cyclophosphamide 
effects are used to inhibit general symptoms and organ involvement [26, 27].
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Among biological drugs, rituximab (anti-CD20 monoclonal antibody) has 
been showing positive results in current clinical trials and is used to inhibit certain 
aspects of the disease. Rituximab improves saliva flow rate and lacrimal gland 
function (discussed), diminishes fatigue and malaise, and is recommended in case 
of cryoglobulinemia or vasculitis-related peripheral nervous system involvement or 
other severe neurologic manifestations of this disease.
Glucocorticosteroids (GCS) are used in immunosuppressive therapy combined 
with other immunosuppressive drugs. Pulses of GCS are used in the case of the 
intensification of organ changes, vasculitis, and nervous system involvement.
Intravenous immunoglobulin administration and plasma exchanges are used in 
life-threatening cases of nervous system involvement and vasculitis.
Other: Vitamin D supplementation and aerobic exercises are recommended.
3.2 Treatment of primary biliary cholangitis
3.2.1 Treatment for itching
Antihistamines, e.g., loratadine or diphenhydramine, are used. Cholestyramine 
as the addition to beverages and foods may be used. Rifampicin, an antibiotic 
which may act as a medicine against itching, may also be administered [28]. Opioid 
antagonists containing naloxone or naltrexone inhibit pruritus by their effects on 
the central nervous system [29].
3.3 Treatment for dry eyes and mouth as in pSS
3.3.1 General treatment
Ursodeoxycholic acid (UDCA) is the main medication used in biliary cholan-
gitis. A complementary therapy with obeticholic acid was introduced in 2016, as 
second-line treatment. If the UDCA treatment is ineffective, the use of fibrates 
(e.g., bezafibrate) in combination therapy (UDCA plus fibrate) is also considered; 
ongoing clinical trials have yielded encouraging results [30]. Of the immunosup-
pressants, the use of methotrexate (MTX), as a drug which may affect pruritus 
score, serum level of alkaline phosphatase, or IgM level, is discussed [31], although 
there were observations that MTX could increase mortality in this group of patients 
[32]. There were clinical trials with rituximab [33] and with ustekinumab [34], but 
at the present time, they have not produced positive results to the expected extent. 
The liver transplant aims at prolonging the patient’s life, but it is reported that up 
to 29% of patients develop a relapse of the disease in the transplanted organ [35]. 
Therefore, the use of UDCA after transplantation is still recommended.
3.3.2 Changes in the style of life
PBC is a chronic autoimmune liver disease in which a lifestyle is particularly impor-
tant. Reducing the intake of foods with high sodium content, avoiding alcohol, as well 
as being careful with new medications or dietary supplements are extremely important. 
Physical exercise is recommended to reduce risk of bone loss and muscle weakness.
4. Conclusions
The epithelium is an important element of the human body due to its protective, 
secretory, and transporting functions. It is also the target for the immunological 
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processes. The impact of environmental, genetic, and epigenetic factors, leading to 
the epithelial cell damage/apoptosis, may cause a breakdown of epithelium hemo-
stasis and the development of autoimmune diseases, Sjögren’s syndrome being its 
prominent representative. For years pSS was associated with autoimmune epithelial 
inflammation and referred to as the “autoimmune epithelitis.” However, the spec-
trum of diseases related to the epithelial autoimmunity is wider including, e.g., pri-
mary biliary cholangitis. The damaged epithelium is a source of autoantigens, and a 
persistent immune cell stimulation may lead to the lymphomas associated with the 
mucosa. Adoption of a wider perspective, combining the clinical experience and 
scientific knowledge, in an approach to the problem of epithelitis enables making 
the connection between emerging symptoms and autoimmune diseases, leading to 
the earlier diagnosis and introduction of proper treatment. Thus the reduction in an 
activity of the immune process and inhibition of further damage to the epithelium 
and of loss of its protective properties can be achieved.
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